SCHEMBL2886146

SCHEMBL2886146

[c]1cccc2ccc(-c3cccc4ncccc34)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.43
FTO Q9C0B1 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
CYP3A4 P08684 1/20 0.41
LMNA P02545 1/20 0.41
BPTF Q12830 1/20 0.39
FYN P06241 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
ERN1 O75460 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
ATR Q13535 1/20 0.37
MAP4K1 Q92918 1/20 0.36
HTR2C P28335 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6988908 0.81 CCR1 (0.48) CNR2CYP3A4LMNACA1CA2
SCHEMBL7918710 0.79 CYP3A4 (0.53) CNR2FTOKDM5BKDM2ACYP3A4
SCHEMBL28609732 0.77 LMNA (0.57) CNR2FTOKDM5BKDM2ACYP3A4
SCHEMBL547268 0.75 FTO (0.42) CNR2FTOKDM5BKDM2ACYP3A4
SCHEMBL14884141 0.74 FTO (0.44) CNR2FTOKDM5BKDM2ACYP3A4
SCHEMBL547112 0.74 ALDH1A1 (0.42) CYP3A4KDM4EALDH1A1CYP1A2NR4A2
SCHEMBL6796273 0.74 CYP1A2 (0.45) KDM4EMAPTALDH1A1CYP1A2
SCHEMBL14884135 0.73 FTO (0.43) CNR2FTOKDM5BKDM2ACYP3A4
SCHEMBL4441864 0.71 PDGFRB (0.41) CA12CA1CA2CA9ERN1
SCHEMBL24475575 0.71 CYP3A4 (0.47) CNR2FTOKDM5BKDM2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029645-A1 Inhibitors of Cytosolic Phospholipase A2 WYETH LLC 2010-02-04 US claimed
US-20100022536-A1 Inhibitors of Cytosolic Phospholipase A2 NOVARTIS AG (CH) 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022536-A1 Inhibitors of Cytosolic Phospholipase A2 PLA2G4B, PLA2G4A, PLA2G12A CNR2 404/4885FTO 4700/4885KDM5B 2549/4885
US-20100029645-A1 Inhibitors of Cytosolic Phospholipase A2 PLA2G4B, PLA2G4A, PLA2G12A CNR2 404/4885FTO 4700/4885KDM5B 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.